Checkpoint Therapeutics, Inc., an immuno-oncology biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's products include CK-301 in Phase I clinical trials for the treatment of non-small cell lung cancer (NSCLC); and CK-101 in the Phase 1 portion of a Phase 1/2 clinical trial for the treatment of epidermal growth factor receptor (EGFR) mutation-positive NSCLC. Its pipeline consists of glucocorticoid-induced TNFR-related protein; and carbonic anhydrase IX. The company is also developing three oral, small-molecule, targeted anti-cancer agents that inhibit epidermal growth-factor receptor mutations, the bromodomain and extra-terminal protein, and poly polymerase. Checkpoint Therapeutics, Inc. has a collaboration agreement with TG Therapeutics, Inc. to develop and commercialize the Anti-PD-L1 and Anti-GITR antibody research programs in the field of hematological malignancies. The company was founded in 2014 and is based in New York, New York. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CKPT
CUSIPN/A
Phone781-652-4500
Debt
Debt-to-Equity RatioN/A
Current Ratio4.84
Quick Ratio4.84
Price-To-Earnings
Trailing P/E Ratio-2.43
Forward P/E Ratio-1.90
P/E GrowthN/A
Sales & Book Value
Annual Sales$1.73 million
Price / Sales47.74
Cash FlowN/A
Price / CashN/A
Book Value$0.59 per share
Price / Book4.37
Profitability
EPS (Most Recent Fiscal Year)($1.00)
Net Income$-22,670,000.00
Net Margins-1,967.93%
Return on Equity-122.20%
Return on Assets-96.27%
Miscellaneous
Employees6
Outstanding Shares32,010,000
Market Cap$82.60
Checkpoint Therapeutics (NASDAQ:CKPT) Frequently Asked Questions
What is Checkpoint Therapeutics' stock symbol?
Checkpoint Therapeutics trades on the NASDAQ under the ticker symbol "CKPT."
How were Checkpoint Therapeutics' earnings last quarter?
Checkpoint Therapeutics Inc (NASDAQ:CKPT) issued its quarterly earnings results on Thursday, May, 10th. The company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.22) by $0.13. The business had revenue of $0.34 million for the quarter. Checkpoint Therapeutics had a negative return on equity of 122.20% and a negative net margin of 1,967.93%. View Checkpoint Therapeutics' Earnings History.
What price target have analysts set for CKPT?
1 equities research analysts have issued 12 month price targets for Checkpoint Therapeutics' shares. Their predictions range from $11.00 to $11.00. On average, they anticipate Checkpoint Therapeutics' stock price to reach $11.00 in the next twelve months. This suggests a possible upside of 326.4% from the stock's current price. View Analyst Ratings for Checkpoint Therapeutics.
What is the consensus analysts' recommendation for Checkpoint Therapeutics?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Checkpoint Therapeutics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
Who are some of Checkpoint Therapeutics' key competitors?
Some companies that are related to Checkpoint Therapeutics include Sienna Biopharmaceuticals (SNNA), Seres Therapeutics (MCRB), Marinus Pharmaceuticals (MRNS), Minerva Neurosciences (NERV), Achaogen (AKAO), Innate Pharma (IPHYF), Kala Pharmaceuticals (KALA), Corbus Pharmaceuticals (CRBP), Corvus Pharmaceuticals (CRVS), Kezar Life Sciences (KZR), Selecta Biosciences (SELB), CELYAD SA/ADR (CYAD), Tyme Technologies (TYME), Corium International (CORI) and Biofrontera (BFRA).
Who are Checkpoint Therapeutics' key executives?
Checkpoint Therapeutics' management team includes the folowing people:
- Mr. James F. Oliviero III, CEO & Pres (Age 42)
- Mr. William Garrett Gray, VP of Fin. & Accounting, Principal Financial Officer and Corp. Sec. (Age 31)
- Ms. Robyn M. Hunter, Corp. Sec. (Age 56)
Has Checkpoint Therapeutics been receiving favorable news coverage?
News stories about CKPT stock have been trending somewhat positive this week, Accern reports. Accern identifies negative and positive news coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Checkpoint Therapeutics earned a news sentiment score of 0.12 on Accern's scale. They also assigned news headlines about the company an impact score of 46.89 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near term.
How do I buy shares of Checkpoint Therapeutics?
Shares of CKPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Checkpoint Therapeutics' stock price today?
One share of CKPT stock can currently be purchased for approximately $2.58.
How big of a company is Checkpoint Therapeutics?
Checkpoint Therapeutics has a market capitalization of $82.60 million and generates $1.73 million in revenue each year. The company earns $-22,670,000.00 in net income (profit) each year or ($1.00) on an earnings per share basis. Checkpoint Therapeutics employs 6 workers across the globe.
How can I contact Checkpoint Therapeutics?
Checkpoint Therapeutics' mailing address is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. The company can be reached via phone at 781-652-4500 or via email at [email protected]
MarketBeat Community Rating for Checkpoint Therapeutics (NASDAQ CKPT)
MarketBeat's community ratings are surveys of what our community members think about Checkpoint Therapeutics and other stocks. Vote "Outperform" if you believe CKPT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CKPT will underperform the S&P 500 over the long term. You may vote once every thirty days.
